Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: Results of a phase-2a placebo-controlled trial

Journal of Viral Hepatitis

Volumn 22, Issue 8, 2015, Pages 651-657

  Halota, W ^a   Ferenci, P ^b   Kozielewicz, D ^a   Dybowska, D ^a   Lisovoder, N ^c   Samira, S ^c   Shalit, I ^c   Ellis, R ^c   Ilan, Y ^d  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

^c NasVax Ltd   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

anti CD3; HCV; oral tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; LIVER ENZYME; OKT 3; PLACEBO; RIBAVIRIN; CD3 ANTIGEN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BURN; CARPAL TUNNEL SYNDROME; CD4+ CD25+ T LYMPHOCYTE; CHOLELITHIASIS; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FATIGUE; FEMALE; FLANK PAIN; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; INCREASED APPETITE; MALE; NAUSEA; ORAL IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REGULATORY T LYMPHOCYTE; RHINOPHARYNGITIS; SCIATICA; VIRUS LOAD; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMOLOGY; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ASPARTATE AMINOTRANSFERASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; LIVER; MALE; MIDDLE AGED; PLACEBOS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84934765248     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12369     Document Type: Article

References (29)

1. Renders L, Valerius T,. Engineered CD3 antibodies for immunosuppression. Clin Exp Immunol 2003; 133: 307-309.
2. Weiner HL, da Cunha AP, Quintana F, et al,. Oral tolerance. Immunol Rev 2011; 241: 241-259.
3. Chen Y, Kuchroo VK, Inobe J, et al,. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240.
4. Weiner HL,. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-214.
5. Zhang X, Izikson L, Liu L, et al,. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol 2001; 167: 4245-4253.
6. Ishikawa H, Ochi H, Chen ML, et al,. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007; 56: 2103-2109.
7. Ochi H, Abraham M, Ishikawa H, et al,. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 2006; 12: 627-635.
8. Wu HY, Quintana FJ, Weiner HL,. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008; 181: 6038-6050.
9. Wu HY, Maron R, Tukpah AM, et al,. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol 2010; 185: 3401-3407.
10. Ilan Y, Maron R, Tukpah AM, et al,. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010; 107: 9765-9770.
11. Ilan Y, Zigmond E, Lalazar G, et al,. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol 2010; 30: 167-177.
12. Halota WFP, Kozielewicz D, Dybowska D, et al,. Oral anti-CD3 immunotherapy for HCV-non-responders is safe, promotes regulatory T cells, and decreases viral load and liver enzyme levels: results of a Phase-2a placebo-controlled trial. J Hepatol 2013; 58 (Suppl. 1): S488-S489.
13. Ip PP, Nijman HW, Wilschut J, et al,. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res 2012; 96: 36-50.
14. Ilyas JA, Vierling JM,. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am 2014; 98: 17-38.
15. Aghemo A, De Francesco R,. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58: 428-438.
16. Dabbouseh NM, Jensen DM,. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 268-276.
17. Gabbay E, Zigmond E, Pappo O, et al,. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13: 5317-5323.
18. Ilan Y,. Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn's disease and chronic hepatitis. Ann N Y Acad Sci 2004; 1029: 286-298.
19. Billerbeck E, Bottler T, Thimme R,. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007; 13: 4858-4864.
20. Heim MH,. Innate immunity and HCV. J Hepatol 2013; 58: 564-574.
21. Brenndorfer ED, Sallberg M,. Hepatitis C virus-mediated modulation of cellular immunity. Arch Immunol Ther Exp 2012; 60: 315-329.
22. Horner SM, Gale M Jr,. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19: 879-888.
23. Ferri C, Cacoub P, Mazzaro C, et al,. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11: 48-55.
24. Rehermann B,. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007; 27: 152-160.
25. Yeh SH, Chuang H, Lin LW, et al,. Tai chi chuan exercise decreases A1C levels along with increase of regulatory T-cells and decrease of cytotoxic T-cell population in type 2 diabetic patients. Diabetes Care 2007; 30: 716-718.
26. Manigold T, Racanelli V,. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007; 7: 804-813.
27. Alatrakchi N, Koziel M,. Regulatory T cells and viral liver disease. J Viral Hepat 2009; 16: 223-229.
28. Rushbrook SM, Hoare M, Alexander GJ,. T-regulatory lymphocytes and chronic viral hepatitis. Exp Opin Biol Ther 2007; 7: 1689-1703.
29. Chiche L, Bataille S, Kaplanski G, et al,. The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol 2012; 2012: 315167.